The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study

Hoskins, William J.; Bundy, Brian N.; Thigpen, J.T.; Omura, George

doi:10.1016/0090-8258(92)90100-w

Cited by 493 publications

(227 citation statements)

References 8 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…The same authors retrospectively reviewed 394 patients from a GOG study all of whom had residual disease <1 cm and concluded that apart from the size of residual disease, the other factors influencing survival are extent of disease, age, tumor grade and the number of residual lesions. [7] The Gynecologic Oncology Group (GOG) has defined optimal debulking as residual implants less than 1 cm. [8] However, Chi et al pointed out, such measurements are subjectively determined at the completion of surgery and due to tissue induration or inadequate exploration, assessments of residual tumor size are often not entirely accurate.…”

Section: Rational For Complete Cytoreductive Surgery (Crs) For Stage mentioning

confidence: 99%

See 1 more Smart Citation

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

show abstract

Section: Rational For Complete Cytoreductive Surgery (Crs) For Stage mentioning

confidence: 99%

“…[11,12] Though spread to these regions is considered indicative of aggressive tumor biology, complete cytoreduction in this area has shown to have a survival benefit as well. [7,13,14].…”

Section: Rational For Complete Cytoreductive Surgery (Crs) For Stage mentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Hacker et al reported that in 47 stage III-IV patients with tumors .10 cm and massive ascites (.10 L), cytoreduction to 1.5 cm RD had a weak (6 months) effect on survival [49,50]. Hoskins et al [22] (GOG study in stage III patients) showed that in the case of optimal debulking, the presence of gross disease in the omentum and at extrapelvic sites had a negative effect on prognosis.…”

Section: Size Of Tumor In Upper Abdomen At Start Of Surgery and Presementioning

confidence: 99%

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer

et al. 2016

View full text Add to dashboard Cite

Background. Standard treatment of stage III and IV advanced ovarian cancer (AOC) consists of primary debulking surgery (PDS) followed by chemotherapy. Since the publication of the European OrganisationforResearchandTreatmentofCancer/NationalCancer Institute of Canada trial, clinical practice has changed and many AOC patients are now treated with neoadjuvant chemotherapy (NACT) followedbyintervaldebulkingsurgery(IDS).Thebestoptionremains unclear. Ovarian cancer is a heterogenic disease. Should we use the diversityinbiologyofthetumorandpatternsoftumorlocalizationto better stratify patients between both approaches? Methods. This analysis was based on results of five phase III randomized controlled trials on PDS and IDS in AOC patients, three Cochrane reviews, and four meta-analyses.

show abstract

“…We completely agree that chemotherapy and the extent of surgical therapy are important prognostic factors in ovarian carcinoma that have been identified by several meta-analyses. [2][3][4][5] Based on these results, platinumbased chemotherapy as well as optimal surgical debulking are now established therapeutic strategies for treatment of ovarian carcinoma.…”

Section: The Function Of Cox-2 In Human Ovarian Carcinomamentioning

confidence: 99%

“…[2][3][4][5] Thus, the therapeutic concept of extensive surgical de-bulking is relevant only for therapy of advanced ovarian carcinoma. Since we included 30% of patients with stage I or II ovarian carcinomas in our study, cytoreductive therapy could not be separately assessed as an independent factor in multivariate analysis for the whole study sample.…”

Section: The Function Of Cox-2 In Human Ovarian Carcinomamentioning

confidence: 99%

The Function of COX-2 in Human Ovarian Carcinoma

Agarwal

Denkert²,

Hauptmann³

2003

The American Journal of Pathology

View full text Add to dashboard Cite

Also, the testicular teratoma 5 showing complete chondrosarcomatous differentiation is an interesting case although the histology shown in the manuscript does not clearly correspond to conventional chondrosarcoma but rather shows additionally undifferentiated mesenchyme. Again, a reinvestigation of the case with currently available tools would be worthwhile, which would allow identification and classification of chondrocyte differentiation. 6,7 Overall, clearly single (ie, very exceptional) cases may exist that represents extreme variants of neoplastic differentiation spectra. Whether this includes chondroma-identical pleomorphic adenoma and chondrosarcoma-identical chondroid chordoma requires further investigations. However, one should not forget, in practice, that these "extreme" cases are very rare-if they exist at all. Thus, particularly in cases in which the neoplastic counterparts (ie, chondrosarcoma for chondroid chordomas) are rather common, one should be very reluctant not to take these as a first diagnostic choice, even though this might, in a very exceptional case, be wrong.

show abstract

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study

Cited by 493 publications

References 8 publications

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer

The Function of COX-2 in Human Ovarian Carcinoma

Contact Info

Product

Resources

About